
Gilead Sciences (GILD) Touches New Record High as 10 Analysts Turn Bullish

I'm PortAI, I can summarize articles.
Gilead Sciences, Inc. (NASDAQ:GILD) reached a new all-time high following strong Q2 earnings, with a 22.5% increase in net income to $1.96 billion and a 1.88% rise in revenues to $7.08 billion. Ten analysts upgraded their ratings to "buy" and "overweight," with Morgan Stanley raising its price target to $143. The company also increased its full-year sales forecast to $28.3-$28.7 billion and upgraded diluted EPS to $5.85-$6.15. Despite this, some analysts suggest that AI stocks may offer greater investment potential.
